Evista is a medicine containing the active ingredient(s) raloxifene. On this page you will find out more about Evista, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: raloxifene
Information for medicine and pack size:
Evista 60 mg film-coated tablet, 28
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Evista is indicated for the prevention and treatment of osteoporosis in post-menopausal women. Evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. Evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
Table of characteristics
White oval film coated tablet with 4165 printed in blue ink on one side
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
28 TABLETS: Prescription Only Medicine, or Prescription Animal Remedy
7 tablets sample pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
What you need to know about Osteoporosis
1.2 million Australians are affected by osteoporosis, which means that their bones are fragile and at risk of fracture. A further 6.3 million people have low bone density (osteopenia), a possible precursor to osteoporosis. However, as many as 4 out of 5 people with osteoporosis don’t know that they have it and therefore don’t know that they are at risk of fracturing a bone. This is because osteoporosis is a ‘silent’ disease without obvious symptoms.
Read more on Osteoporosis Australia website
Found 0 results